Praecis/Amgen Abarelix-Depot Spares Patients Initial Testosterone Surge
Executive Summary
Praecis/Amgen's abarelix-depot lowers testosterone levels in prostate cancer patients without the initial testosterone surge associated with luteinizing hormone releasing hormone agonists such as TAP's Lupron Depot, according to posters presented May 23 at the American Society for Clinical Oncology annual meeting in New Orleans.
You may also be interested in...
Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"
Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).
Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"
Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).
Pharmacia Trelstar Depot Approval Gives Company Prostate Cancer Therapy
Pharmacia will add a prostate cancer therapy to its oncology products portfolio following approval of Trelstar Depot June 15.